文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

中性粒细胞经CD80/CTLA-4通路介导脓毒症小鼠T淋巴细胞功能障碍

[Neutrophils mediate T lymphocyte function in septic mice via the CD80/cytotoxic T lymphocyte antigen-4 signaling pathway].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2021-01-01
一句话结论脓毒症小鼠中中性粒细胞通过CD80/CTLA-4通路抑制T细胞IL-2分泌,CTLA-4抗体可提高96小时生存率并恢复T细胞功能。

该研究为动物实验(小鼠)与体外细胞实验,探讨脓毒症时中性粒细胞对T淋巴细胞功能的影响及CD80/CTLA-4通路的作用。CLP脓毒症小鼠脾、骨髓及外周血中性粒细胞CD80表达上调,脾T细胞表面CTLA-4表达升高至(9.98±0.84)%(对照3.48±0.64)%。腹腔注射CTLA-4抗体(50 μg,术后6小时和24小时)使CLP小鼠96小时累积生存率从18.75%升至56.25%,并提高T细胞CD69表达。体外实验显示LPS刺激使中性粒细胞CD80时间依赖性升高,中性粒细胞与T细胞共培养增加CD4+/CD8+ T细胞CTLA-4表达并抑制IL-2分泌,CTLA-4抗体可部分恢复IL-2。提示CD80/CTLA-4通路是脓毒症免疫治疗潜在靶点。

要点

  • CLP脓毒症小鼠脾T细胞表面CTLA-4表达显著高于假手术组[(9.98±0.84)% vs. (3.48±0.64)%,P<0.05]。
  • CTLA-4抗体(50 μg腹腔注射,术后6小时和24小时)使CLP小鼠96小时累积生存率从18.75%提高至56.25%(P<0.05)。
  • LPS(1 mg/L)刺激健康小鼠骨髓中性粒细胞后CD80表达时间依赖性升高,12小时达(19.83±1.06)%(对照5.16±0.36)%。
  • CTLA-4抗体(体外终浓度50 mg/L)可部分恢复共培养体系中T细胞的IL-2分泌。

适用人群与场景

  • 6-8周龄雄性C57BL/6小鼠,CLP诱导脓毒症模型;假手术组仅行相同操作但不结扎穿刺盲肠。
  • 体外实验使用健康小鼠骨髓来源中性粒细胞及脾脏T淋巴细胞。

诊断标准与关键阈值

  • 脓毒症模型采用盲肠结扎穿孔(CLP)法复制。
  • 原文未提及临床诊断标准、评分界值或启动/停止阈值。

处置流程与药物剂量

  • 体内实验:CTLA-4抗体50 μg于术后6小时和24小时腹腔注射,用于CLP脓毒症小鼠。
  • 体外实验:CTLA-4抗体终浓度50 mg/L加入共培养体系,48小时后检测IL-2。
  • LPS体外刺激浓度1 mg/L,分别刺激4、8、12小时。
  • 原文未提及人体给药剂量、途径、频次或目标值。

红旗征与不能漏的情况

  • 原文未提及临床红旗征或需紧急处理的情况。

研究设计与关键结果

  • 研究类型:动物体内实验与体外细胞实验;样本量:Sham组n=20、Sham+aCTLA-4组n=20、CLP组n=30、CLP+aCTLA-4组n=30。
  • 主要结果:CLP小鼠脾T细胞CTLA-4表达升高[(9.98±0.84)% vs. (3.48±0.64)%,P<0.05];CTLA-4抗体提高96小时累积生存率(56.25% vs. 18.75%,P<0.05)及T细胞CD69表达。
  • 体外:LPS刺激中性粒细胞CD80时间依赖性升高(4h 6.35±0.40% vs. 3.41±0.40%;8h 8.57±0.64% vs. 3.09±0.27%;12h 19.83±1.06% vs. 5.16±0.36%,均P<0.05);中性粒细胞共培养增加CD4+ T细胞CTLA-4至(4.92±0.30)%(对照3.33±0.25)%及CD8+至(4.26±0.21)%(对照2.53±0.66)%,LPS刺激中性粒细胞后更高
  • 不良事件:原文未提及。

证据类型、等级与局限

  • 证据类型:动物实验与体外细胞实验(非临床研究)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:样本为小鼠,脓毒症模型为CLP,结果不能直接外推至人类;CTLA-4抗体体内剂量(50 μg/只)与体外浓度(50 mg/L)不同,原文未提供人体剂量;单中心动物实验,原文未报告盲法与样本量计算。

对床旁实践的改变

  • 该研究提示CD80/CTLA-4通路参与脓毒症T细胞功能障碍,CTLA-4抗体可能成为脓毒症免疫治疗新方法,但证据仅来自小鼠与体外实验。
  • 不改变当前急诊/ICU对脓毒症患者的常规诊疗;原文未提供人体适用人群、剂量或安全性数据,不能据此在临床使用CTLA-4抗体。
  • 常见陷阱:将小鼠96小时生存率获益(56.25% vs. 18.75%)直接等同于临床疗效;将动物实验剂量外推至人。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the effect of neutrophils on T lymphocyte function in septic mice and the role of CD80/cytotoxic T lymphocyte antigen-4 (CTLA-4) signaling pathway in this modulated effects.

METHODS: (1) In vivo experiment: 6-8 weeks old male C57BL/6 mice were divided into sham operation group (Sham group, n = 20), Sham+CTLA-4 antibody treatment group (Sham+aCTLA-4 group, n = 20), cecum ligation and perforation (CLP) induced sepsis model group (CLP group, n = 30) and CLP+CTLA-4 antibody treatment group (CLP+aCTLA-4 group, n = 30) according to the random number table. CLP was used to reproduce mouse sepsis model. The mice in the Sham group were treated identically but their cecums were neither punctured nor ligated. In CTLA-4 antibody treatment groups, 50 μg CTLA-4 antibody was injected intraperitoneally 6 hours and 24 hours after the operation. Forty-eight hours after operation, 6 mice in Sham group and Sham+aCTLA-4 group, 14 mice in CLP group and CLP+aCTLA-4 group were randomly selected to detect the expression of CD69 in spleen. At the same time, spleen, bone marrow and peripheral blood were collected, and the expression of CD80 on neutrophils was detected by flow cytometry. The expression of CTLA-4 on the surface of T lymphocytes in spleen was detected by immunofluorescence and flow cytometry. The remaining mice in each group were used to observe the 96-hour survival after operation. (2) In vitro experiment 1: neutrophils were extracted from bone marrow of healthy mice and stimulated with LPS (1 mg/L) for 4, 8 and 12 hours respectively. The control group was added with the same amount of phosphate buffer saline (PBS) at each time point, and the expression of CD80 was detected at each time point. (3) In vitro experiment 2: splenic T lymphocytes of healthy mice were extracted and divided into PBS control group, LPS group (final concentration of LPS 1 mg/L), neutrophil group and neutrophil+LPS group. In the latter two groups, the co-culture model of neutrophils and T lymphocytes was established, and then the corresponding treatment was given to detect the expression of CTLA-4 on the surface of T lymphocytes. With the above four groups as controls, CTLA-4 antibody treatment groups (final concentration of CTLA-4 antibody 50 mg/L) were set up respectively. After 48 hours, the level of interleukin-2 (IL-2) in the cell supernatant was detected by enzyme linked immunosorbent assay (ELISA).

RESULTS: (1) Results of in vivo experiment: compared with Sham group, the expression of CD80 on neutrophils in spleen, bone marrow and peripheral blood was significantly up-regulated, while the expression of CTLA-4 on the surface of T lymphocytes was significantly increased [(9.98±0.84)% vs. (3.48±0.64)%, P < 0.05]. It suggested that neutrophils may affect T lymphocytes function through CD80/CTLA-4 pathway in sepsis. Compared with CLP group, CTLA-4 antibody could significantly improve the 96-hour cumulative survival rate of CLP mice (56.25% vs. 18.75%, P < 0.05), and increase the expression of CD69 on the surface of T lymphocytes. It suggested that CTLA-4 antibodies might increase T lymphocytes activation in sepsis and improve survival. (2) Results of in vitro experiment: with the prolongation of LPS stimulation, the expression of CD80 on neutrophils gradually increased in time-dependent manner as compared with PBS control group [4 hours: (6.35±0.40)% vs. (3.41±0.40)%, 8 hours: (8.57±0.64)% vs. (3.09±0.27)%, 12 hours: (19.83±1.06)% vs. (5.16±0.36)%, all P < 0.05]. Compared with PBS control group, the expression of CTLA-4 on CD4+/CD8+ T lymphocytes was not significantly affected by LPS stimulation alone, but CTLA-4 was increased after co-culture with neutrophils [CD4+: (4.92±0.30)% vs. (3.33±0.25)%, CD8+: (4.26±0.21)% vs. (2.53±0.66)%, both P < 0.05], and the increased trend of CTLA-4 was more obvious after co-culture with LPS-stimulated neutrophils [CD4+: (6.34±0.50)% vs. (3.33±0.25)%, CD8+: (6.21±0.41)% vs. (2.53±0.66)%, both P < 0.05]. In the PBS control group and LPS group, CTLA-4 antibody had no significant effect on IL-2 secretion of T lymphocytes. Compared with PBS control group, co-culture with neutrophils could inhibit the secretion of IL-2 by T lymphocytes (ng/L: 1 938.00±68.45 vs. 2 547.00±218.00, P < 0.05), and the inhibitory effect of neutrophils stimulated by LPS was more obvious (ng/L: 1 073.00±34.39 vs. 2 547.00±218.00, P < 0.05). CTLA-4 antibodies could partially restore IL-2 secretion. In conclusion, after promoting the expression of CTLA-4 on the surface of T lymphocytes, neutrophils might mediate the inhibition of T lymphocytes function by reducing the production of IL-2.

CONCLUSIONS: Neutrophils mediate T lymphocytes dysfunction in sepsis, and the CD80/CTLA-4 pathway plays an important role. The CTLA-4 antibody improves survival and T lymphocytes function in sepsis mice, which may be a new method of immunotherapy for sepsis.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Sun R, Huang J, Liu L, et al. [Neutrophils mediate T lymphocyte function in septic mice via the CD80/cytotoxic T lymphocyte antigen-4 signaling pathway]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34412756. doi:10.3760/cma.j.cn121430-20210113-00047

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。